Botanical extract from vietnamese plant tested for safety in first human trial
NCT ID NCT07300202
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested the safety of a single dose of Orialpha (BD-C), a drug made from the Uvaria grandiflora plant, in 15 healthy adults aged 18 to 60. Researchers monitored side effects and determined the highest safe dose. The study does not test whether the drug works against breast cancer, but it is a first step toward future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orialpha (BD-C), a botanical extract from the Uvaria grandiflora plant
What this could lead to
If safe, this could pave the way for future studies testing Orialpha as a potential treatment for breast cancer.
What could go wrong
This is a very early Phase I safety study in only 15 healthy people. It does not test whether the drug works against cancer, and many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanoi Medical University
Hanoi, Hanoi, 100000, Vietnam